WBR0660: Difference between revisions

Jump to navigation Jump to search
Newer edit →
VisualWikitext
Rim Halaby (talk | contribs)
CMEUser, Bureaucrats, nocaptcha, Administrators
27,346 edits
Created page with "{{WBRQuestion |QuestionAuthor={{Rim}} |ExamType=USMLE Step 1 |MainCategory=Biostatistics/ Epidemiology |SubCategory=Gastrointestinal |MainCategory=Biostatistics/ Epidemiology ..."
 
Sergekorjian (talk | contribs)
CMEUser, Bots, Bureaucrats, bureaucrats, editnews, interwiki, nocaptcha, nukepages, oversight, smwadministrator, Administrators, Widget editors
5,932 edits
No edit summary
Line 1: Line 1:
{{WBRQuestion
{{WBRQuestion
|QuestionAuthor={{Rim}}
|QuestionAuthor={{SSK}} (Reviewed by Serge Korjian)
|ExamType=USMLE Step 1
|ExamType=USMLE Step 1
|MainCategory=Biostatistics/ Epidemiology
|SubCategory=Gastrointestinal
|SubCategory=Gastrointestinal
|MainCategory=Biostatistics/ Epidemiology
|SubCategory=Gastrointestinal
|SubCategory=Gastrointestinal
|MainCategory=Biostatistics/ Epidemiology
|SubCategory=Gastrointestinal
|SubCategory=Gastrointestinal
|MainCategory=Biostatistics/ Epidemiology
|MainCategory=Biostatistics/ Epidemiology
|SubCategory=Gastrointestinal
|SubCategory=Gastrointestinal
|MainCategory=Biostatistics/ Epidemiology
|SubCategory=Gastrointestinal
|SubCategory=Gastrointestinal
|MainCategory=Biostatistics/ Epidemiology
|SubCategory=Gastrointestinal
|SubCategory=Gastrointestinal
|MainCategory=Biostatistics/ Epidemiology
|SubCategory=Gastrointestinal
|SubCategory=Gastrointestinal
|MainCategory=Biostatistics/ Epidemiology
|MainCategory=Biostatistics/ Epidemiology
|SubCategory=Gastrointestinal
|SubCategory=Gastrointestinal
|Prompt=A new vaccine is being developed for the prevention of Hepatitis E. In phase 3 of the clinical trial, a group of 100 people is randomized to receive either the vaccine or placebo. Out of the 50 patients that received the vaccine 1 went on to develop Hepatitis E in the 6 month follow up after the vaccination. In the placebo group 7 out of 50 patients developed Hepatitis. What is the number needed to treat for this newly developed vaccine according to the results of this trial?  
|Prompt=A new vaccine is being developed for the prevention of Hepatitis E. In a phase 2 clinical trial, 100 individuals are randomized to receive either the vaccine or a placebo. Out of the 50 patients that received the vaccine 1 went on to develop Hepatitis E in the 6 month follow up after the vaccination. In the placebo group 7 out of 50 patients developed Hepatitis. What is the number needed to treat for this newly developed vaccine according to the results of this trial?
|Explanation=The number needed to treat refers to the number of patients required to receive a certain treatment for 1 patient to benefit from it. It is usually the inverse of the absolute risk reduction(ARR). The ARR can be calculated as follows:
|Explanation=The number needed to treat refers to the number of patients required to receive a certain treatment for 1 patient to benefit from it. It is usually the inverse of the absolute risk reduction(ARR). The ARR can be calculated as follows:


[[Image:ARRequation.jpg|600px]]
[[Image:ARRequation.jpg|600px]]
Educational objective: The number needed to treat is calculated by finding the inverse of the absolute risk reduction (1/ARR)
|AnswerA=0.14
|AnswerA=0.14
|AnswerB=7.14
|AnswerB=7.14
Line 32: Line 19:
|AnswerD=300
|AnswerD=300
|AnswerE=Data insufficient to calculate
|AnswerE=Data insufficient to calculate
|EducationalObjectives=The number needed to treat is calculated by finding the inverse of the absolute risk reduction (1/ARR)
|RightAnswer=C
|RightAnswer=C
|WBRKeyword=Number needed to treat
|WBRKeyword=Number needed to treat, Absolute risk reduction
|Approved=No
|Approved=Yes
}}
}}

Revision as of 01:12, 16 September 2014
Author [[PageAuthor::Serge Korjian M.D. (Reviewed by Serge Korjian)]]
Exam Type ExamType::USMLE Step 1
Main Category
Sub Category SubCategory::Gastrointestinal
Prompt [[Prompt::A new vaccine is being developed for the prevention of Hepatitis E. In a phase 2 clinical trial, 100 individuals are randomized to receive either the vaccine or a placebo. Out of the 50 patients that received the vaccine 1 went on to develop Hepatitis E in the 6 month follow up after the vaccination. In the placebo group 7 out of 50 patients developed Hepatitis. What is the number needed to treat for this newly developed vaccine according to the results of this trial?]]
Answer A AnswerA::0.14
Answer A Explanation AnswerAExp::
Answer B AnswerB::7.14
Answer B Explanation AnswerBExp::
Answer C AnswerC::8.33
Answer C Explanation AnswerCExp::
Answer D AnswerD::300
Answer D Explanation AnswerDExp::
Answer E AnswerE::Data insufficient to calculate
Answer E Explanation AnswerEExp::
Right Answer RightAnswer::C
Explanation [[Explanation::The number needed to treat refers to the number of patients required to receive a certain treatment for 1 patient to benefit from it. It is usually the inverse of the absolute risk reduction(ARR). The ARR can be calculated as follows:


Educational Objective: The number needed to treat is calculated by finding the inverse of the absolute risk reduction (1/ARR)
References: ]]

Approved Approved::Yes
Keyword WBRKeyword::Number needed to treat, WBRKeyword::Absolute risk reduction
Linked Question Linked::
Order in Linked Questions LinkedOrder::
Retrieved from "https://www.wikidoc.org/index.php?title=WBR0660&oldid=1021955"